BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND TRRAP, TR-AP, 8295, ENSG00000196367, Q9Y4A5, PAF400, PAF350/400, FLJ10671, STAF40, Tra1
1118 results:

  • 1. Infection risk reduction with povidone-iodine rectal disinfection prior to transrectal prostate biopsy: an updated systematic review and meta-analysis.
    Tsuboi I; Matsukawa A; Parizi MK; Klemm J; Mancon S; Chiujdea S; Fazekas T; Laukhtina E; Kawada T; Katayama S; Iwata T; Bekku K; Wada K; Araki M; Shariat SF
    World J Urol; 2024 Apr; 42(1):252. PubMed ID: 38652324
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Challenges in Diagnosis and Treatment of Male Hypogonadism.
    Purnamasari D
    Acta Med Indones; 2024 Jan; 56(1):1-2. PubMed ID: 38561883
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Open-top Bessel beam two-photon light sheet microscopy for three-dimensional pathology.
    Park WY; Yun J; Shin J; Oh BH; Yoon G; Hong SM; Kim KH
    Elife; 2024 Mar; 12():. PubMed ID: 38488831
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Plasma metabolites and risk of seven cancers: a two-sample Mendelian randomization study among European descendants.
    Chen Y; Xie Y; Ci H; Cheng Z; Kuang Y; Li S; Wang G; Qi Y; Tang J; Liu D; Li W; Yang Y
    BMC Med; 2024 Mar; 22(1):90. PubMed ID: 38433226
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Combining magnetic resonance imaging with a multi-ancestry polygenic risk score to improve identification of clinically significant prostate cancer.
    Plym A; Madueke I; Naik S; Isabelle M; Conti DV; Haiman CA; Penney KL; Mucci LA; Khorasani R; Kibel AS
    JNCI Cancer Spectr; 2024 Feb; 8(2):. PubMed ID: 38429995
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Very high-energy electron therapy as light-particle alternative to transmission proton FLASH therapy - An evaluation of dosimetric performances.
    Böhlen TT; Germond JF; Desorgher L; Veres I; Bratel A; Landström E; Engwall E; Herrera FG; Ozsahin EM; Bourhis J; Bochud F; Moeckli R
    Radiother Oncol; 2024 May; 194():110177. PubMed ID: 38378075
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. prostate cancer Screening Uptake in Transgender Women.
    Kalavacherla S; Riviere P; Kalavacherla S; Anger JT; Murphy JD; Rose BS
    JAMA Netw Open; 2024 Feb; 7(2):e2356088. PubMed ID: 38353948
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. The effect of limited english proficiency on prostate-specific antigen screening in American men.
    Stone BV; Labban M; Beatrici E; Filipas DK; Frego N; Qian ZJ; Voleti SS; Osman NY; Pomerantz MM; Lipsitz SR; Feldman AS; Kibel AS; Cole AP; Trinh QD
    World J Urol; 2024 Jan; 42(1):54. PubMed ID: 38244128
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Enhancing Metabolome Annotation by Electron Impact Excitation of Ions from Organics-Molecular Networking.
    Wang X; Sun X; Wang F; Wei C; Zheng F; Zhang X; Zhao X; Zhao C; Lu X; Xu G
    Anal Chem; 2024 Jan; 96(4):1444-1453. PubMed ID: 38240194
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Worsening of 2-year patient-reported intestinal functionality after radiotherapy for prostate cancer including pelvic node irradiation.
    Sanguineti G; Pavarini M; Munoz F; Magli A; Cante D; Garibaldi E; Gebbia A; Noris Chiorda B; Girelli G; Villa E; Faiella A; Magdalena Waskiewicz J; Avuzzi B; Pastorino A; Moretti E; Rago L; Statuto T; Gatti M; Rancati T; Valdagni R; Luigi Vavassori V; Gisella Di Muzio N; Fiorino C; Cozzarini C
    Radiother Oncol; 2024 Mar; 192():110088. PubMed ID: 38199284
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial.
    Markowski MC; Taplin ME; Aggarwal R; Sena LA; Wang H; Qi H; Lalji A; Sinibaldi V; Carducci MA; Paller CJ; Marshall CH; Eisenberger MA; Sanin DE; Yegnasubramanian S; Gomes-Alexandre C; Ozbek B; Jones T; De Marzo AM; Denmeade SR; Antonarakis ES
    Nat Commun; 2024 Jan; 15(1):14. PubMed ID: 38167882
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Risk of Biochemical Recurrence in Patients With Grade Group 1 prostate cancer With Extraprostatic Extension Treated With Radical prostatectomy.
    Rezaee ME; Pallauf M; Fletcher SA; Han M; Pavlovich CP; Cornelia Ding CK; Epstein JI; Allaf ME; Trock BJ; Singla N
    J Urol; 2024 Mar; 211(3):407-414. PubMed ID: 38109699
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study.
    Grande E; Arranz JÁ; De Santis M; Bamias A; Kikuchi E; Del Muro XG; Park SH; De Giorgi U; Alekseev B; Mencinger M; Izumi K; Schutz FA; Puente J; Li JR; O'Donnell PH; Kalebasty AR; Ye D; Mariathasan S; Bene-Tchaleu F; Bernhard S; Lee C; Davis ID; Galsky MD
    Lancet Oncol; 2024 Jan; 25(1):29-45. PubMed ID: 38101433
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study.
    Bamias A; Davis ID; Galsky MD; Arranz JÁ; Kikuchi E; Grande E; Del Muro XG; Park SH; De Giorgi U; Alekseev B; Mencinger M; Izumi K; Schutz FA; Puente J; Li JR; Panni S; Gumus M; Özgüroğlu M; Mariathasan S; Poloz Y; Bene-Tchaleu F; Lee C; Bernhard S; De Santis M
    Lancet Oncol; 2024 Jan; 25(1):46-61. PubMed ID: 38101431
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN.
    Shen J; Chowdhury S; Agarwal N; Karsh LI; Oudard S; Gartrell BA; Feyerabend S; Saad F; Pieczonka CM; Chi KN; Brookman-May SD; Rooney B; Bhaumik A; McCarthy SA; Bevans KB; Mundle SD; Small EJ; Smith MR; Graff JN
    Br J Cancer; 2024 Jan; 130(1):73-81. PubMed ID: 37951974
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. prostate cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for prostate cancer Rotterdam.
    de Vos II; Remmers S; Hogenhout R; Roobol MJ;
    Eur Urol; 2024 Jan; 85(1):74-81. PubMed ID: 37919190
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. A tumour-spheroid manufacturing and cryopreservation process that yields a highly reproducible product ready for direct use in drug screening assays.
    Shajib MS; Futrega K; Davies AM; Franco RAG; McKenna E; Guillesser B; Klein TJ; Crawford RW; Doran MR
    J R Soc Interface; 2023 Oct; 20(207):20230468. PubMed ID: 37817581
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. cancer Prevalence Projections in Japan and Decomposition Analysis of Changes in cancer Burden, 2020-2050: A Statistical Modeling Study.
    Nguyen PT; Hori M; Matsuda T; Katanoda K
    Cancer Epidemiol Biomarkers Prev; 2023 Dec; 32(12):1756-1770. PubMed ID: 37756571
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. A review of recent advancements in Actinium-225 labeled compounds and biomolecules for therapeutic purposes.
    Hassan M; Bokhari TH; Lodhi NA; Khosa MK; Usman M
    Chem Biol Drug Des; 2023 Nov; 102(5):1276-1292. PubMed ID: 37715360
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Prehabilitative versus rehabilitative exercise in prostate cancer patients undergoing prostatectomy.
    Singh F; Newton RU; Taaffe DR; Lopez P; Thavaseelan J; Brown M; Ooi E; Nosaka K; Hayne D; Galvão DA
    J Cancer Res Clin Oncol; 2023 Dec; 149(18):16563-16573. PubMed ID: 37712960
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 56.